

## Selzentry<sup>®</sup> (maraviroc) – First-time generic

- On February 7, 2022, [Camber Pharmaceuticals launched Hetero's AB-rated](#) generic version of ViiV Healthcare's [Selzentry \(maraviroc\)](#) 150 mg and 300 mg tablets.
- Selzentry is approved in combination with other antiretroviral agents for the treatment of only chemokine coreceptor 5 (CCR5)--tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 2 kg.
- Selzentry is also available as brand 25 mg and 75 mg tablets, and oral solution.
- Selzentry carries a boxed warning for hepatotoxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.